https://orcid.org/0000-0002-0477-5546
Figures & data
Figure 1. All potential genes, overlapping target proteins of oxyresveratrol and liver cancer identified from respective public databases
Figure 2. PPI network with 13 crucial targets in oxyresveratrol against liver cancer by using string assay
Figure 3. Bar diagram of GO-based biological processes associated with anti-liver cancer functions of oxyresveratrol
Figure 4. Bar chart of KEGG-based signaling pathways involved in anti-liver cancer mechanisms of oxyresveratrol
Figure 5. Oxyresveratrol-crucial targets-signaling pathway-liver cancers integrated networks
Figure 6. Molecular docking interaction between potent binding capabilities of oxyresveratrol and target proteins. (a) Binding energy parameters; (b) ESR1 (PDB ID: 1UOM); (c) EGFR (PDB ID: 5UGC); (d) SRC (PDB ID: 4K11); (e) AR (PDB ID: 2AM9); (f) TNF (PDB ID: 6OOY); (g) PTGS2 (PDB ID: 5IKR); (h) PIK3CA (PDB ID: 6PYS); (i) PGR (PDB ID: 1A28); (j) MMP9 (PDB ID: 4XCT)
Figure 7. Validated determination in human liver cancer samples based on network pharmacology and molecular docking findings
Figure 8. Validated experiments in oxyresveratrol-treated liver cancer cells according to network pharmacology and molecular docking data
